SkyePharma's asthma drug Flutiform could face US delay
This article was originally published in Scrip
Executive Summary
The US FDA has given SkyePharma a preliminary notice of some potential review issues for its combination asthma drug Flutiform (fluticasone propionate plus formoterol fumarate). Additional clinical work may be required to provide more data on dosing, potentially causing a delay to regulatory approval, the UK company says.